Sugi Predict

Sugi Predict / Targets / HDAC6

HDAC6

Protein deacetylase HDAC6 · Q9UBN7 · HDAC6 on Sugi Atlas →

882,278 patent compounds predicted against HDAC6, 526,873 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vorinostat Vorinostat (SCHEMBL9018) 1.00 16/20
SCHEMBL28250 SCHEMBL28250 0.57 14/20
SCHEMBL29476 SCHEMBL29476 0.57 14/20
SCHEMBL19539 SCHEMBL19539 0.52 14/20
SCHEMBL28328 SCHEMBL28328 0.61 13/20
SCHEMBL28329 SCHEMBL28329 0.61 13/20
SCHEMBL28330 SCHEMBL28330 0.61 13/20
SCHEMBL29695 SCHEMBL29695 0.61 13/20
SCHEMBL28688 SCHEMBL28688 0.46 13/20
SCHEMBL29014 SCHEMBL29014 0.46 13/20
SCHEMBL29015 SCHEMBL29015 0.46 13/20
Trichostatin Trichostatin (SCHEMBL19886) 1.00 12/20
SCHEMBL21138 SCHEMBL21138 0.55 12/20
SCHEMBL21139 SCHEMBL21139 0.55 12/20
SCHEMBL21140 SCHEMBL21140 0.55 12/20
SCHEMBL18565 SCHEMBL18565 0.48 11/20
SCHEMBL28840 SCHEMBL28840 0.61 10/20
SCHEMBL28841 SCHEMBL28841 0.61 10/20
SCHEMBL28842 SCHEMBL28842 0.61 10/20
SCHEMBL19479 SCHEMBL19479 0.45 10/20

Clinical trials — most relevant to HDAC6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. PHASE2COMPLETED
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer PHASE2UNKNOWN
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome PHASE1RECRUITING
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours PHASE1COMPLETED
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome PHASE1RECRUITING
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer EARLY_PHASE1WITHDRAWN
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HDAC6 binder may also engage these)

ProteinNameSimilarity
Q9Z2V5 — 0.998 Q9Z2V5 →
A0A8I6GM68 — 0.994 A0A8I6GM68 →
Q8VDP3 — 0.980 Q8VDP3 →
D3ZBP4 — 0.978 D3ZBP4 →
F1QCV2 — 0.976 F1QCV2 →
Q8TDZ2 — 0.975 Q8TDZ2 →
Q9ESK3 — 0.975 Q9ESK3 →
F1MH07 — 0.974 F1MH07 →
P52790 — 0.973 P52790 →
P49222 — 0.973 P49222 →
P10937 — 0.973 P10937 →
Q3ZBE0 — 0.972 Q3ZBE0 →
Q9DA79 — 0.972 Q9DA79 →
Q8N490 — 0.972 Q8N490 →
A7YY46 — 0.972 A7YY46 →
ENGASE Cytosolic endo-beta-N-acetylglucosaminidase 0.972 landscape →
Q9H611 — 0.972 Q9H611 →
Q8K4F6 — 0.971 Q8K4F6 →
Q91ZJ0 — 0.971 Q91ZJ0 →
Q767M3 — 0.971 Q767M3 →
Q5BJS0 — 0.971 Q5BJS0 →
P51176 — 0.971 P51176 →
Q02401 — 0.971 Q02401 →
Q91W34 — 0.971 Q91W34 →
Q96SM3 — 0.971 Q96SM3 →
Q9H4B8 — 0.971 Q9H4B8 →
Q3SYT1 — 0.971 Q3SYT1 →
P51839 — 0.971 P51839 →
P48760 — 0.970 P48760 →
Q80SX8 — 0.970 Q80SX8 →